Gly-Coramin

Hauptinformation

  • Handelsname:
  • Gly-Coramin Lutschtabletten
  • Darreichungsform:
  • Lutschtabletten
  • Zusammensetzung:
  • nicethamidum 125 mg, glucose monohydricum 200 mg Glukose-Flüssigkeit, Zucker 1.138 g, excipiens für die Torte.
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • Biologische Medizin

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Gly-Coramin Lutschtabletten
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Synthetika
  • Therapiebereich:
  • Tonikum

Weitere Informationen

Status

  • Quelle:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Zulassungsnummer:
  • 25385
  • Berechtigungsdatum:
  • 10-06-1959
  • Letzte Änderung:
  • 24-10-2018

Packungsbeilage

Patienteninformation

Gly-Coramin®

HÄNSELER

Was ist Gly-Coramin und wann wird es angewendet?

Gly-Coramin enthält Traubenzucker (Glucose), der Energie spendet, und Nikethamid, das die

Atmung anregend beeinflussen kann. Gly-Coramin kann angewendet werden bei:

Ermüdungserscheinungen bei körperlichen Anstrengungen sowie bei Beschwerden, die durch einen

Höhenaufenthalt oder Luftdruckveränderungen wie z.B. beim Berggehen hervorgerufen werden.

Was sollte dazu beachtet werden?

Hinweis für Diabetiker: Gly-Coramin enthält Rohrzucker (Saccharose) und ist deshalb für Diabetiker

nicht geeignet.

Hinweis für Sportler: Die Einnahme von Gly-Coramin kann eine positive Reaktion bei Antidoping-

Kontrollen zur Folge haben.

1 Lutschtablette enthält 2,7 g Kohlenhydrate (= 0,27 Brotwerte).

Wann darf Gly-Coramin nicht angewendet werden?

Bei bekannter Überempfindlichkeit gegenüber in Gly-Coramin enthaltenen Substanzen sowie bei

Epilepsie, Porphyrie (eine Stoffwechselerkrankung) und Bluthochdruck.

Wann ist bei der Einnahme von Gly-Coramin Vorsicht geboten?

Gly-Coramin enthält Traubenzucker (Glucose) sowie Rohrzucker (Saccharose) und ist deshalb für

Diabetiker nicht geeignet.

Informieren Sie Ihren Arzt, Apotheker oder Drogisten bzw. Ihre Ärztin, Apothekerin oder Drogistin,

wenn Sie an anderen Krankheiten leiden, Allergien haben oder andere Arzneimittel (auch

selbstgekaufte!) einnehmen oder äusserlich anwenden.

Darf Gly-Coramin während einer Schwangerschaft oder in der Stillzeit eingenommen werden?

Wenn Sie schwanger sind oder es werden möchten und während der Stillzeit sollten Sie Gly-

Coramin nicht einnehmen. Schwangerschaftsbedingte Ermüdungserscheinungen sollen nicht mit

Gly-Coramin behandelt werden.

Wie verwenden Sie Gly-Coramin?

Die Wirkung von Gly-Coramin wird rasch verspürt.

Erwachsene und Jugendliche ab 16 Jahren: 1 Lutschtablette im Munde zergehen lassen. In der Regel

können auf den Tag verteilt bis zu ca. 10 Lutschtabletten eingenommen werden. Gly-Coramin soll

bei Kindern und Jugendlichen unter 16 Jahren nicht angewendet werden.

Halten Sie sich an die in der Packungsbeilage angegebene oder vom Arzt oder der Ärztin

verschriebene Dosierung. Wenn Sie glauben, das Arzneimittel wirke zu schwach oder zu stark, so

sprechen Sie mit Ihrem Arzt, Apotheker oder Drogisten bzw. mit Ihrer Ärztin, Apothekerin oder

Drogistin.

Welche Nebenwirkungen kann Gly-Coramin haben?

Für Gly-Coramin sind bisher keine Nebenwirkungen beobachtet worden. Wenn Sie dennoch

Nebenwirkungen bemerken, sollten Sie Ihren Arzt, Apotheker oder Drogisten bzw. Ihre Ärztin,

Apothekerin oder Drogistin informieren.

Was ist ferner zu beachten?

Arzneimittel sollen für Kinder unerreichbar aufbewahrt werden, Gly-Coramin insbesondere wegen

der Verwechslungsgefahr mit Bonbons.

Vor Feuchtigkeit schützen und bei Raumtemperatur (15–25 °C) lagern. Das Arzneimittel darf nur bis

zu dem auf dem Behälter mit «EXP» bezeichneten Datum verwendet werden.

Weitere Auskünfte erteilt Ihnen Ihr Arzt, Apotheker oder Drogist bzw. Ihre Ärztin, Apothekerin oder

Drogistin.

Was ist in Gly-Coramin enthalten?

1 Lutschtablette enthält: 125 mg Nikethamid, 200 mg Glucose in Form von Stärkesirup, 1,1 g

Saccharose sowie Aromastoffe.

Zulassungsnummer

25385 (Swissmedic).

Wo erhalten Sie Gly-Coramin? Welche Packungen sind erhältlich?

In Apotheken und Drogerien, ohne ärztliche Verschreibung.

Packung zu 30 Lutschtabletten.

Zulassungsinhaberin

Hänseler AG, 9101 Herisau.

Diese Packungsbeilage wurde im April 2012 letztmals durch die Arzneimittelbehörde (Swissmedic)

geprüft.

11-9-2018

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Botanicals and preparations derived from these are among the substances frequently added to foods and food supplements, yet the safety of many botanicals has not been systematically assessed. In the context of the EU‐FORA fellowship programme, the fellow performed an assessment on the safety of the botanical Gymnema sylvestre, in accordance with EFSA's guidance on the assessment of safety of botanicals. Although preparations of G. sylvestre are marketed as f...

Europe - EFSA - European Food Safety Authority Publications

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

3-8-2018

Apricot kernels pose a risk of cyanide poisoning

Apricot kernels pose a risk of cyanide poisoning

A familiar ingredient for jam-makers, apricot kernels are increasingly being consumed as a natural remedy for their claimed "anti-cancer" properties. While one kernel added to perfume several jars of jam is not a problem, ingesting them in large quantities exposes consumers to the risk of cyanide poisoning. ANSES has identified several cases of apricot kernel poisoning in France through its toxicovigilance scheme, and encourages consumers to exercise caution.

France - Agence Nationale du Médicament Vétérinaire

18-5-2018

7K and Poseidon 4500 by Shoreside Enterprises: Voluntary Recall - Due to Presence of Undeclared Sildenafil and/or Tadalafil

7K and Poseidon 4500 by Shoreside Enterprises: Voluntary Recall - Due to Presence of Undeclared Sildenafil and/or Tadalafil

Use of products with the undeclared active ingredients, sildenafil and tadalafil, may pose a threat to consumers because the active ingredient may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may cause a significant drop in blood pressure that may be life threatening. Among the adult male population who are most likely to use these products, adult males who use nitrates for cardiac conditions are the most at risk from these products. These products are considered ta...

FDA - U.S. Food and Drug Administration

17-6-2011

Warning against dangerous arthritis product Beline Capsules

Warning against dangerous arthritis product Beline Capsules

The Danish Medicines Agency warns strongly against taking the arthritis product Beline Capsules based on analyses made by the Danish Medicines Agency and the Medical Products Agency in Sweden.

Danish Medicines Agency

14-12-2010

Warning against dangerous "natural" potency-enhancing product

Warning against dangerous "natural" potency-enhancing product

The Danish Medicines Agency strongly warns against using the potency-enhancing product marketed as POWERtabs based on information from the Norwegian drug regulatory authorities that a Norwegian man needed treatment after having taken the potency-enhancing product.

Danish Medicines Agency

11-3-2010

Strengthened warning against Alscreme 'Creme  nr. 2' from www.eminescu.dk

Strengthened warning against Alscreme 'Creme nr. 2' from www.eminescu.dk

On 12 February 2010, the Danish Medicines Agency warned strongly against using the product Alscreme 'Creme nr. 2' sold via www.eminescu.dk, as the product is an unlicensed medicinal product that contains active substance clobetasol.

Danish Medicines Agency

16-2-2010

Warning against ‘Alscreme Creme nr. 2’ from www.eminescu.dk

Warning against ‘Alscreme Creme nr. 2’ from www.eminescu.dk

The Danish Medicines Agency warns strongly against use of the product 'Alscreme Creme nr. 2' sold via www.eminescu.dk, as the product is an unauthorised medicinal product containing the active substance clobetasol.

Danish Medicines Agency

22-12-2009

Warning against the potency-enhancing product Rock Hard Weekend

Warning against the potency-enhancing product Rock Hard Weekend

The Danish Medicines Agency strongly warns against using the potency-enhancing product Rock Hard Weekend after the FDA (U.S. Food and Drug Administration) has notified the Danish Medicines Agency that Rock Hard Weekend contains an undeclared active substance and that the product has been exported from the USA to Denmark.

Danish Medicines Agency

9-12-2009

Warning against the weight-loss product Super Slim

Warning against the weight-loss product Super Slim

The Danish Medicines Agency strongly warns against using the weight-loss product Super Slim. We do so based on a warning from the Swedish Medical Products Agency against Super Slim, which is sold on the internet.

Danish Medicines Agency

27-5-2008

Danish Medicines Agency warns against the weight-loss product Therma Power

Danish Medicines Agency warns against the weight-loss product Therma Power

The Danish Medicines Agency strongly warns against Therma Power Red and similar products with the same content and characteristics. Therma Power Red contains ephedrine and is illegal in Denmark.

Danish Medicines Agency

30-1-2008

The Danish Medicines Agency and the Danish Veterinary and Food Administration warn against the weight loss product Therma Power

The Danish Medicines Agency and the Danish Veterinary and Food Administration warn against the weight loss product Therma Power

The Danish Medicines Agency strongly warns against Therma Power and products with a similar content and characteristics. Therma Power contains ephedrine or synephrine and is illegal in Denmark.

Danish Medicines Agency

1-10-2018

EU/3/16/1762 (Pharma Gateway AB)

EU/3/16/1762 (Pharma Gateway AB)

EU/3/16/1762 (Active substance: Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker) - Transfer of orphan designation - Commission Decision (2018)6399 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/107/16/T/01

Europe -DG Health and Food Safety

21-8-2018

Onglyza® 2,5 mg/5 mg Filmtabletten

Rote - Liste

15-8-2018

Komboglyze (AstraZeneca AB)

Komboglyze (AstraZeneca AB)

Komboglyze (Active substance: saxagliptin / metformin) - Centralised - 2-Monthly update - Commission Decision (2018)5559 of Wed, 15 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2059/WS/1289

Europe -DG Health and Food Safety

6-8-2018

Onglyza (AstraZeneca AB)

Onglyza (AstraZeneca AB)

Onglyza (Active substance: saxagliptin) - Centralised - 2-Monthly update - Commission Decision (2018)5387 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1039/WS/1289/45

Europe -DG Health and Food Safety

2-8-2018

EU/3/18/2047 (Glycomine SARL)

EU/3/18/2047 (Glycomine SARL)

EU/3/18/2047 (Active substance: Liposomal mannose-1-phosphate) - Orphan designation - Commission Decision (2018)5279 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/055/18

Europe -DG Health and Food Safety

11-7-2018

Seebri Breezhaler (Novartis Europharm Limited)

Seebri Breezhaler (Novartis Europharm Limited)

Seebri Breezhaler (Active substance: glycopyrronium bromide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4513 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2430/T/27

Europe -DG Health and Food Safety

11-7-2018

Tovanor Breezhaler (Novartis Europharm Limited)

Tovanor Breezhaler (Novartis Europharm Limited)

Tovanor Breezhaler (Active substance: glycopyrronium bromide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4526 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2690/T/30

Europe -DG Health and Food Safety

4-7-2018

Enurev Breezhaler (Novartis Europharm Limited)

Enurev Breezhaler (Novartis Europharm Limited)

Enurev Breezhaler (Active substance: glycopyrronium bromide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4342 of Wed, 04 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2691/T/27

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2027 (Regeneron Ireland U.C.)

EU/3/18/2027 (Regeneron Ireland U.C.)

EU/3/18/2027 (Active substance: Three human monoclonal antibodies against the Ebola virus glycoprotein) - Orphan designation - Commission Decision (2018)3395 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/008/18

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2023 (Dr Regenold GmbH)

EU/3/18/2023 (Dr Regenold GmbH)

EU/3/18/2023 (Active substance: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-actinium) - Orphan designation - Commission Decision (2018)3391 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/252/17

Europe -DG Health and Food Safety

24-5-2018

Ultibro Breezhaler (Novartis Europharm Limited)

Ultibro Breezhaler (Novartis Europharm Limited)

Ultibro Breezhaler (Active substance: indacaterol/glycopyrronium bromide) - Centralised - Renewal - Commission Decision (2018)3259 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2679/R/24

Europe -DG Health and Food Safety

24-5-2018

Xoterna Breezhaler (Novartis Europharm Limited)

Xoterna Breezhaler (Novartis Europharm Limited)

Xoterna Breezhaler (Active substance: indacaterol/glycopyrronium bromide) - Centralised - Renewal - Commission Decision (2018)3265 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3755/R/27

Europe -DG Health and Food Safety

18-5-2018

EU/3/13/1220 (IQVIA RDS Ireland Limited)

EU/3/13/1220 (IQVIA RDS Ireland Limited)

EU/3/13/1220 (Active substance: Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}ethyl]sulfanyl}-3-{[(2S)-1-ethoxy-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}propanamido)-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)propanoyl Ethyl ester) )-methoxy]acetyl}oxy)butyl)sulfanyl]-3-(hexadecylcarbamoyl)propanoic acid]-poly(ethylene glycol)-este...

Europe -DG Health and Food Safety

15-5-2018

Ulunar Breezhaler (Novartis Europharm Limited)

Ulunar Breezhaler (Novartis Europharm Limited)

Ulunar Breezhaler (Active substance: indacaterol/glycopyrronium bromide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3058 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3875/T/24

Europe -DG Health and Food Safety

2-5-2018

Trydonis (Chiesi Farmaceutici S.p.A.)

Trydonis (Chiesi Farmaceutici S.p.A.)

Trydonis (Active substance: beclometasone / formoterol / glycopyrronium bromide) - Centralised - Authorisation - Commission Decision (2018)2713 of Wed, 02 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4702

Europe -DG Health and Food Safety

26-4-2018

Riarify (Chiesi Farmaceutici S.p.A.)

Riarify (Chiesi Farmaceutici S.p.A.)

Riarify (Active substance: beclometasone / formoterol / glycopyrronium bromide) - New authorisation - Commission Decision (2018)2581 of Thu, 26 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4836

Europe -DG Health and Food Safety